Next Article in Journal
Clinical Response of Metastatic Breast Cancer to Multi-targeted Therapeutic Approach: A Single Case Report
Next Article in Special Issue
Molecular Epidemiology of Female Lung Cancer
Previous Article in Journal
Breast Cancer-Initiating Cells: Insights into Novel Treatment Strategies
Previous Article in Special Issue
Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
Cancers 2011, 3(1), 1426-1453; doi:10.3390/cancers3011426
Review

The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer

,
 and *
Received: 29 December 2010; in revised form: 9 March 2011 / Accepted: 10 March 2011 / Published: 17 March 2011
(This article belongs to the Special Issue Lung Cancer)
View Full-Text   |   Download PDF [308 KB, uploaded 17 March 2011]   |   Browse Figure
Abstract: Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin are the most commonly used cytotoxic chemotherapeutic agents to treat the disease. These agents, usually combined with drugs such as gemcitabine or pemetrexed, induce objective tumor responses in only 20–30% of patients. Aberrant epigenetic regulation of gene expression is a frequent event in NSCLC. In this article we review the emerging evidence that epigenetics and the cellular machinery involved with this type of regulation may be key elements in the development of cisplatin resistance in NSCLC.
Keywords: epigenetics; histone; post-translational modification; DNA methylation; epigenetic modifiers; cisplatin; NSCLC epigenetics; histone; post-translational modification; DNA methylation; epigenetic modifiers; cisplatin; NSCLC
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

O’Byrne, K.J.; Barr, M.P.; Gray, S.G. The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. Cancers 2011, 3, 1426-1453.

AMA Style

O’Byrne KJ, Barr MP, Gray SG. The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. Cancers. 2011; 3(1):1426-1453.

Chicago/Turabian Style

O’Byrne, Kenneth J.; Barr, Martin P.; Gray, Steven G. 2011. "The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer." Cancers 3, no. 1: 1426-1453.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert